Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
Fungal Phylum Microsporidia01:28

Fungal Phylum Microsporidia

Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
Fungal Group Zygomycota01:29

Fungal Group Zygomycota

Zygomycota, previously classified as a distinct fungal group, are primarily terrestrial, saprophytic molds that play a crucial role as decomposers. Recent phylogenetic studies have revealed that these fungi are now divided into two major clades — Mucoromycota, which includes many symbiotic species, and Zoopagomycota, which primarily consists of parasitic and pathogenic fungi. These groups exhibit distinct ecological roles and reproductive strategies while sharing key structural and...
Fungal Phylum Basidiomycota01:26

Fungal Phylum Basidiomycota

Basidiomycota is a diverse phylum of fungi that includes ecologically significant decomposers such as white rot fungi, symbionts like mycorrhizal fungi, plant pathogens such as rusts and smuts, and edible species like Agaricus bisporus (the common button mushroom). These fungi play crucial roles in nutrient cycling, symbiotic relationships, and even human health. Their defining feature is the basidium, a microscopic club-shaped structure responsible for producing basidiospores.Fruiting Bodies...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Etest ECVs/ECOFFs for Detection of Resistance in Prevalent and Three Nonprevalent <i>Candida</i> spp. to Triazoles and Amphotericin B and Aspergillus spp. to Caspofungin: Further Assessment of Modal Variability.

Antimicrobial agents and chemotherapy·2021
Same author

Method-Dependent Epidemiological Cutoff Values for Detection of Triazole Resistance in <i>Candida</i> and <i>Aspergillus</i> Species for the Sensititre YeastOne Colorimetric Broth and Etest Agar Diffusion Methods.

Antimicrobial agents and chemotherapy·2018
Same author

Multicenter Study of Method-Dependent Epidemiological Cutoff Values for Detection of Resistance in Candida spp. and Aspergillus spp. to Amphotericin B and Echinocandins for the Etest Agar Diffusion Method.

Antimicrobial agents and chemotherapy·2016
Same author

In vitro activity of anidulafungin in combination with amphotericin B or voriconazole against biofilms of five Candida species.

The Journal of antimicrobial chemotherapy·2016
Same author

In Vitro Studies of Tigemonam: a Comparison of the Minimum Inhibitory and Minimum Bactericidal Concentrations (MIC vs MBC).

Journal of chemotherapy (Florence, Italy)·2016
Same author

Erratum to: Species distribution and in vitro antifungal susceptibility profiles of yeast isolates from invasive infections during a Portuguese multicenter survey.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2015
Same journal

Nasal swab-guided deescalation of empirical linezolid in respiratory infections at a secondary-level hospital: quantification of quality gaps and antimicrobial stewardship opportunities.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2026
Same journal

[Infectious complications following intravesical bacillus Calmette-Guérin therapy: a case series].

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2026
Same journal

Long-term persistence, effectiveness, safety, and metabolic impact of bictegravir/emtricitabine/tenofovir alafenamide fixed-dose combination in people living with HIV in the BICTARG cohort.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2026
Same journal

Associations between high-risk human papillomavirus genotypes: evidence of HPV16 predominance as a monoinfection and its no stronger link with high-grade lesions.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2026
Same journal

Pediatric septic arthritis caused by <i>Staphylococcus argenteus</i>.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2026
Same journal

[Colonisation or early invasion? Disseminated aspergillosis after bronchial isolation of <i>Aspergillus fumigatus</i> in a heart transplant recipient].

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2026
See all related articles

Related Experiment Video

Updated: Jul 4, 2026

Automation of Bio-Atomic Force Microscope Measurements on Hundreds of C. albicans Cells
09:27

Automation of Bio-Atomic Force Microscope Measurements on Hundreds of C. albicans Cells

Published on: April 2, 2021

[Anidulafungin].

M Gobernado1, E Cantón

  • 1Servicio de Microbiología, Hospital La Fe, Avenida Campanar 21, Valencia. gobernado_mig@gva.es

Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia
|May 30, 2008
PubMed
Summary
This summary is machine-generated.

Anidulafungin, a new antifungal, effectively treats Candida infections, including resistant strains, with a favorable safety profile and no necessary dose adjustments for organ insufficiency. It offers a suitable alternative for various candidiasis therapies.

More Related Videos

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus
12:29

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus

Published on: April 19, 2017

Candida albicans Biofilm Chip (CaBChip) for High-throughput Antifungal Drug Screening
08:05

Candida albicans Biofilm Chip (CaBChip) for High-throughput Antifungal Drug Screening

Published on: July 18, 2012

Related Experiment Videos

Last Updated: Jul 4, 2026

Automation of Bio-Atomic Force Microscope Measurements on Hundreds of C. albicans Cells
09:27

Automation of Bio-Atomic Force Microscope Measurements on Hundreds of C. albicans Cells

Published on: April 2, 2021

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus
12:29

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus

Published on: April 19, 2017

Candida albicans Biofilm Chip (CaBChip) for High-throughput Antifungal Drug Screening
08:05

Candida albicans Biofilm Chip (CaBChip) for High-throughput Antifungal Drug Screening

Published on: July 18, 2012

Area of Science:

  • Pharmacology
  • Mycology
  • Infectious Diseases

Background:

  • Anidulafungin is a novel echinocandin antifungal agent.
  • It targets 1,3-β-D-glucan synthesis, a key fungal cell wall component absent in mammals, minimizing toxicity.
  • It exhibits fungicidal activity against Candida species, including fluconazole-resistant strains, and fungistatic activity against Aspergillus species.

Purpose of the Study:

  • To evaluate the efficacy and safety of anidulafungin as an antifungal agent.
  • To compare anidulafungin with fluconazole for invasive and non-invasive Candida infections.
  • To assess the pharmacokinetic properties and drug-interaction profile of anidulafungin.

Main Methods:

  • Clinical trials were conducted to assess anidulafungin's efficacy and safety.
  • Non-inferiority to fluconazole was evaluated for various Candida infections.
  • Pharmacokinetic studies examined half-life, degradation, and drug interactions.

Main Results:

  • Anidulafungin demonstrated non-inferiority to fluconazole in treating invasive and non-invasive Candida infections.
  • The drug is well-tolerated with no reported serious drug-related adverse events.
  • Anidulafungin has a long half-life, is degraded by human peptidases/proteases, and has minimal drug-drug interactions, not requiring dose adjustments for renal or hepatic insufficiency.

Conclusions:

  • Anidulafungin is a safe and effective alternative for treating mucosal candidiasis, candidemia, and invasive candidiasis.
  • Its favorable pharmacokinetic profile and low interaction potential make it suitable for combination therapy and in patients with renal or hepatic insufficiency.
  • The drug is generally well-tolerated, with common adverse events including nausea, vomiting, diarrhea, and transient hepatic enzyme elevation.